Correlation of neuroendocrine features with prognosis of non-small cell lung cancer
Metrics: PDF 1024 views | HTML 1012 views | ?
Jianguo Feng1,2,*, Huaying Sheng3,*, Chihong Zhu2, Xiaoqian Qian2, Danying Wan2, Dan Su1,2, Xufeng Chen4, Liming Zhu5
1Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China
2Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China
3Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China
4Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
5Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China
*These authors contributed equally to this work
Liming Zhu, email: firstname.lastname@example.org
Keywords: non-small cell lung cancer, neuroendocrine, CD56, CgA, Syn
Received: June 20, 2016 Accepted: September 21, 2016 Published: September 28, 2016
The improvement in histological diagnostic tools, including neuroendocrine markers by immunohistochemistry (IHC), has led to increased recognition of non-small cell lung cancer (NSCLC) with neuroendocrine (NE) feature. However, little is known regarding the prevalence and clinical implications of NE feature in patients with NSCLC. In this study, we performed IHC in a tissue microarray containing 451 Chinese NSCLC cases, and analyzed correlation of the expression of neuroendocrine marker with pathological and clinical features of NSCLC. The result showed that NE feature in NSCLC was detectable in almost 30% of studied patients, and tumors with NE feature were significantly correlated with pathological classification, clinical stages and cell differentiation of NSCLC. Our data also revealed that NE feature indicated worse overall survival and disease free survival. Compared with mutant p53, NE markers showed more significance as for prognostic evaluation. Multi-factor COX analysis further suggested a potential clinical impact for NE feature as an independent indicator of poor prognosis for NSCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.